PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsAcarbose
Acarbose
Acarbose (acarbose) is an oligosaccharide pharmaceutical. Acarbose was first approved as Precose on 1995-09-06. It is used to treat type 2 diabetes mellitus in the USA. It is known to target maltase-glucoamylase and pancreatic alpha-amylase.
Download report
Favorite
Searched
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nutritional and metabolic diseasesD009750
endocrine system diseasesD004700
Trade Name
FDA
EMA
Acarbose (discontinued: Acarbose, Precose)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Acarbose
Tradename
Company
Number
Date
Products
PRECOSEBayerN-020482 DISCN1995-09-06
3 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
acarboseANDA2025-01-20
precoseNew Drug Application2014-05-29
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A10: Drugs used in diabetes
— A10B: Blood glucose lowering drugs, excl. insulins
— A10BD: Combinations of oral blood glucose lowering drugs
— A10BD17: Metformin and acarbose
— A10BF: Alpha glucosidase inhibitors, blood glucose lowering
— A10BF01: Acarbose
HCPCS
No data
Clinical
Clinical Trials
113 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 2 diabetes mellitusD003924EFO_0001360E115316291668
Diabetes mellitusD003920EFO_0000400E08-E131314261659
OverweightD050177—E66.323—127
Glucose intoleranceD018149HP_0000833R73.03———516
Coronary diseaseD003327————23—5
ObesityD009765EFO_0001073E66.9—1—315
Coronary artery diseaseD003324—I25.1——13—4
Myocardial ischemiaD017202EFO_1001375I20-I25——13—4
Cardiovascular diseasesD002318EFO_0000319I98——1113
AtherosclerosisD050197EFO_0003914I25.1——1113
Show 20 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Glucose metabolism disordersD044882————1—12
Metabolic diseasesD008659EFO_0000589E88.9——1—12
HypertensionD006973EFO_0000537I10——1——1
HypercholesterolemiaD006937————1——1
Gestational diabetesD016640—O24.4——1——1
Pregnancy in diabeticsD011254—O24.91——1——1
Metabolic syndromeD024821EFO_0000195E88.810——1——1
InflammationD007249MP_0001845———1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HypotensionD007022EFO_0005251I9512———3
AgingD000375GO_0007568R41.81—2———2
SyncopeD013575—G90.01—1———1
Body weightD001835EFO_0004338—11———1
Liver diseasesD008107EFO_0001421K70-K77—1———1
Non-alcoholic fatty liver diseaseD065626EFO_0003095K75.81—1———1
Fatty liverD005234EFO_0003934——1———1
Renal cell carcinomaD002292EFO_0000376——1———1
Kidney neoplasmsD007680EFO_0003865C64—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Pure autonomic failureD054970——1————1
Orthostatic hypotensionD007024—I95.11————1
Congenital hyperinsulinismD044903——1————1
NesidioblastosisD046768EFO_0007318E16.91————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
StrokeD020521EFO_0000712I63.9————22
Heart failureD006333EFO_0003144I50————22
PancreatitisD010195EFO_0000278K85————22
Polycystic ovary syndromeD011085EFO_0000660E28.2————22
Transient ischemic attackD002546EFO_0003764G45.9————11
Pathologic constrictionD003251——————11
StentsD015607——————11
Ischemic strokeD000083242——————11
Cognitive dysfunctionD060825—G31.84————11
Pancreatic neoplasmsD010190EFO_0003860C25————11
Show 6 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameAcarbose
INNacarbose
Description
(2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol is a glycoside and an amino cyclitol.
Classification
Oligosaccharide
Drug class—
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O
Identifiers
PDB—
CAS-ID56180-94-0
RxCUI—
ChEMBL IDCHEMBL1566
ChEBI ID—
PubChem CID444254
DrugBankDB00284
UNII IDT58MSI464G (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
AMY2A
AMY2A
Organism
Homo sapiens
Gene name
AMY2A
Gene synonyms
NCBI Gene ID
Protein name
pancreatic alpha-amylase
Protein synonyms
1,4-alpha-D-glucan glucanohydrolase, amylase alpha 2A (pancreatic), glycogenase, pancreatic amylase alpha 2A
Uniprot ID
Mouse ortholog
—
—
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Acarbose
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 11,750 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
2,562 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use